Related Experiment Video
Updated: Mar 21, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
The role of PRDMs in cancer: one family, two sides
Slim Mzoughi1, Ying Xim Tan2, Diana Low2
1Institute of Molecular and Cell Biology (IMCB), A*STAR (Agency for Science, Technology and Research), 61 Biopolis Drive, Proteos Building #3-06, 138673 Singapore, Singapore; Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, 8 Medical Drive, Singapore 117597, Singapore.
Abstract:
The PRDM family of proteins share a unique structure, with an N-terminal PR domain, which has a potential methyltransferase activity, followed by a distinct number of zinc fingers at the C-terminus, potentially mediating protein-protein, protein-RNA or protein-DNA interactions. Interestingly, despite no comprehensive functional data, all family members have been associated with deletions, mutations, epigenetic silencing or overexpression, in multiple cancer types. The intriguing observation is that different isoforms exist for almost all PRDM family members. These isoforms are not only differentially regulated, but play opposite roles in cancer, in what has been termed 'Yin and Yang' regulation, typical of this class of epigenetic regulators. Collectively, these findings set the stage for future intervention, by targeting directly their intrinsic catalytic activities, or indirectly, pathways that differentially regulate tumor suppressor/oncogenic isoform-expression.
More Related Videos
Related Concept Videos
Abnormal Proliferation
Cancer Survival Analysis
Targeted Cancer Therapies
There are several types of targeted therapies against...
Mitogens and the Cell Cycle

